Evidence map›Paper›PMID 35187508›Full record

ArticleBiomaterials and biosystems2022

Engineered extracellular vesicles antagonize SARS-CoV-2 infection by inhibiting mTOR signaling.

A G Ibrahim, A Ciullo, C Li, G Garcia, K Peck, K Miyamoto, V Arumugaswami, E Marbán

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomaterials and biosystems, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Post-acute Sequelae in COVID-19 Survivors: an Overview.SN comprehensive clinical medicine · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

A G IbrahimSmidt Heart Institute, Cedars Sinai Medical Center, Los Angeles, CA, USA.
A CiulloSmidt Heart Institute, Cedars Sinai Medical Center, Los Angeles, CA, USA.
C LiSmidt Heart Institute, Cedars Sinai Medical Center, Los Angeles, CA, USA.
G GarciaDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
K PeckSmidt Heart Institute, Cedars Sinai Medical Center, Los Angeles, CA, USA.
K MiyamotoSmidt Heart Institute, Cedars Sinai Medical Center, Los Angeles, CA, USA.
V ArumugaswamiDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
E MarbánSmidt Heart Institute, Cedars Sinai Medical Center, Los Angeles, CA, USA.
Cedars-Sinai Medical Center · USUniversity of California, Los Angeles · US

Funding

Interplay between AMPK and Hippo Signaling Regulates Ocular Antiviral Response to Zika virus infectionR01EY032149 · NEI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Vaithilingaraja Arumugaswami, Ashok Kumar · 2021 to 2026
$2.8M
Macrophages as effectors of cell therapy for heart failureR01HL142579 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI IBRAHIM, AHMED · 2019 to 2023
$2.1M
NEI NIH HHS R01 EY032149NHLBI NIH HHS R01 HL142579
6 · The paper itself

Abstract

Effective treatment approaches for patients with COVID-19 remain limited and are neither curative nor widely applicable. Activated specialized tissue effector extracellular vesicles (ASTEX) derived from genetically-enhanced skin fibroblasts, exert disease-modifying bioactivity

Indexed as

ASTEX, Activated specialized tissue effector extracellular vesiclesCovid-19Covid-19, Coronavirus disease 2019Engineered cellsEVs, Extracellular vesiclesExtracellular vesiclesmTORmTOR, Mammalian target of rapamycinSARS-CoV-2SARS-CoV-2, Severe acute respiratory syndrome coronavirus-2Viral replication

Identifiers

PMID35187508
PMCPMC8841010
OpenAlexW4213330734

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.